¤@¡³¤T¦~«×¤º¬ì±M¬ìÂå®v¦Ò¸Õµ§¸ÕÃD -- ¦å²G¬ì

(C) 1. ¹L¥h¥¼´¿±µ¨üheparinª`®g¹L¤§¯f¤H¡Aª`®gheparin«á¤Þµo¦å¤pªO§C¤U(Heparin induced thrombocytopenia)³Ì±`¥X²{ªº®É¶¡¬°heparinª`®g«á
A.1¤Ñ¤º
B.1¦Ü3¤Ñ
C.5¦Ü10¤Ñ
D.14¦Ü28¤Ñ
E.1­Ó¤ë«á
 
(C) 2. ¤U¦C¦³ÃöTRALI(transfusion-related acute lung injury)ªº±Ô­z¦óªÌ¦³»~¡H
A.¿éª`¥ô¦ó¦å²G¦¨¤À³£¦³¥i¯àµo¥Í
B.¤@¯ë¦b¿é¦å¤¤©Î¿é¦å«á6¤p®É¤ºµo¥Í
C.µo¥Íªº­ì¦]¥i¯à»P¨ü¦åªÌÅ餺¦³§Ü®½¦åªÌ¥Õ¦å²yªº§ÜÅ馳Ãö
D.¯f¤Hªº¯Ý³¡X¥ú·|¥X²{¨âÃäªÍ¸­ªº®û¼í
E.¥Ø«e¨ÃµL©ú½TÃÒ¾ÚÅã¥ÜÃþ©T¾JªvÀø¦³®Ä
 
(E) 3. ¤@¦ì63·³¨k©Ê¦b°·±dÀˬd®É°¸µMµo²{¦å¤pªO¼Æ¬°732,000/uL¡A¦å¬õ¯À¤Î¥Õ¦å²yµL²§±`¡F¨­ÅéÀˬd(physical examination)¨ÃµL¯S®íµo²{¡A°ò¦]ÀË´ú¥¼µo²{¦³JAK2¬ðÅÜ¡C¤U¦C¦óºØÀˬdµ²ªG¹ï­ìµo©Ê¦å¤pªO¼W¥Í¯gªº¶EÂ_³Ì¦³À°§U¡H
A.°©ÅèÅK¬V¦â¥i¬Ý¨ìring sideroblasts
B.¶O«°¬V¦âÅ鶧©Ê
C.PDGFRA°ò¦]¬ðÅÜ
D.EGFR°ò¦]¬ðÅÜ
E.CALR°ò¦]¬ðÅÜ
 
(D) 4. ¤@¦ì¯f¤H¦b©â¦åÀˬd¤¤µo²{PT¬°16.3"(¥¿±`9.8~11.5")¡AINR 1.52¡APTT¬°54.3"(¥¿±`25.6~32.6")¡C¯f¤H³Ì¤£¥i¯à¦³¥H¤U¦óºØª¬ªp¡H
A.Warfarin treatment
B.Rivaroxaban treatment
C.Aspirin treatment
D.Factor XII deficiency
E.Liver disease
 
(A) 5. ¤@¦ì52·³¯f¤H©â¦åÀˬdµo²{¥Õ¦å²y¼Æ¬°25,500/uL¡A²O¤Ú²Ó­M¦û78%¡A©PÃä¦å²G©Ù¤ù¦p¹Ï©Ò¥Ü¡A¬y¤ó²Ó­M»öÅã¥Ü³o¨Ç²O¤Ú²Ó­Mªí²{CD19¡ACD20¡ACD5¡ACD23¡A¤Î£e-»´Ãì¡A¦ýµLCD3¡ACD10¤Î£f-»´Ãìªí²{¡A¦¹¯f¤H³Ì¥i¯à±o¤F¤°»ò¯f¡H
A.Chronic lymphocytic leukemia
B.Large granular lymphocyte leukemia
C.Reactive lymphocytosis
D.Acute lymphoblastic leukemia
E.Follicular lymphoma
 
(E) 6. ¤@¦ì17·³¨k©Ê¯f¤H¦]µo¿N¦í°|¡A¦å²GÀˬdÅã¥Ü¬õ¦å²y2,350,000/uL¡A¥Õ¦å²y1,050/uL¡A¨ä¤¤segmented forms 10%¡Abands 2%¡Alymphocytes 82%¡Amonocytes 6%¡A¦å¤pªO16,400/uL¡Aºôª¬¬õ¦å²y1%¡F¨Ï¥Î§Ü¥Í¯À«á¡AÅé·Å¦^´_¥¿±`¡C°©ÅèÀˬdÅã¥Ü¬°¦A¥Í¤£¨}©Ê³h¦å¡A¤U¤@¨B³Ì¾A·íªºªvÀø¬°¦ó¡H
A.Antithymocyte globulin
B.Cyclosporine
C.Antithymocyte globulin¤Îcyclosporine
D.Anabolic hormone
E.Allogeneic hematopoietic stem cell transplantation from a HLA-matched sibling donor
 
(C) 7. ¤@¦hµo©Ê°©Åè½F±wªÌ¡A¦å²GÀˬdÅã¥Ü¦å¬õ¯À10.5 gm/dL¡A¥Õ³J¥Õ3.6 gm/dL¡A²y³J¥Õ5.1 gm/dL¡ACr 1.1 mg/dL¡A£]2-microglobulin 4.1 mg/L¡A¦¹¯f¤H¦b°ê»Ú¤À´Á¨t²Î(International Staging System)¤§´Á§O¬°¡H
A.0
B.I
C.II
D.III
E.IV
 
(E) 8. ¤@¦ì47·³¨k©Ê·s¶EÂ_¥X¦³ºC©Ê°©Åè©Ê¥Õ¦å¯f¡A¤U¦C¦³Ãö¦¹¯f¤Hªº±Ô­z¦óªÌ¬O¥¿½Tªº¡H(À³¿ï¥X©Ò¦³¥¿½Tµª®×) (1)¦³¬V¦âÅ鲧±`t(9;22) (2)¦³²§±`¤§¿Ä¦X°ò¦]BCR-ABL (3)³Ì¾A·íªºªvÀø¬°¹TÓi»Ä¿EúC§í¨î¾¯(tyrosine kinase inhibitor)
A.(1)
B.(2)
C.(1)+(2)
D.(1)+(3)
E.(1)+(2)+(3)
 
(B) 9. ¤@¦ì58·³¤k©Ê¡A¦]ÀV³¡²O¤Úµ²¸~¤j±µ¨ü¤Á¤ùÀˬd¡A¯f²zªì¨B³ø§i¬°ºÃ¦üÂoªw«¬²O¤Ú½F(follicular lymphoma)¡C¤U¦C¦óºØÀˬdµ²ªG¥i¥HÀ°¦£¶EÂ_Âoªw«¬²O¤Ú½F¡H(À³¿ï¥X©Ò¦³¥¿½Tµª®×) (1) t(14;18) (2) BCL-2²§±`ªí²{ (3) CD5²Ó­Mªí­±§Ü­ì¶§©Ê
A.(1)
B.(1)+(2)
C.(1)+(3)
D.(2)+(3)
E.(1)+(2)+(3)
 
(E) 10. ¤U¦C¦óºØª¬ªp¦³¥i¯à³y¦¨¥þ¦å²y´î¤Ö¡H(À³¿ï¥X©Ò¦³¥¿½Tµª®×) (1) Vit B12 deficiency (2) Myelodysplastic syndrome (3) Liver cirrhosis (4) Autoimmune disease
A.(4)
B.(2)+(4)
C.(2)+(3)
D.(2)+(3)+(4)
E.(1)+(2)+(3)+(4)
 


< ¤@¡³¤T¦~«×¸ÕÃD¥Ø¿ý >